Litigation Details for In re HIV Antitrust Litigation (N.D. Cal. 2019)
✉ Email this page to a colleague
In re HIV Antitrust Litigation (N.D. Cal. 2019)
| Docket | ⤷ Try a Trial | Date Filed | 2019-05-14 |
| Court | District Court, N.D. California | Date Terminated | |
| Cause | 15:1 Antitrust Litigation | Assigned To | Edward Milton Chen |
| Jury Demand | Both | Referred To | Laurel D. Beeler |
| Parties | BLUECHOICE HEALTHPLAN OF SOUTH CAROLINA, INC.; FWK HOLDINGS, LLC | ||
| Patents | 6,043,230; 6,642,245; 6,703,396; 7,390,791; 7,803,788; 8,592,397; 8,598,185; 8,754,065; 8,841,310; 9,018,192; 9,296,769; 9,545,414 | ||
| Attorneys | Matthew R. Wisnieff; Peter J. Carney | ||
| Firms | Hagens Berman Sobol Shapiro LLP; Holland & Knight, LLP; Lock Lord LLP, Managing Partner, San Francisco Office | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in In re HIV Antitrust Litigation
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Biologic Drugs cited in In re HIV Antitrust Litigation
The biologic drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for In re HIV Antitrust Litigation (N.D. Cal. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-05-14 | 1 | Complaint | 5,935,946; 5,977,089; and 6,043,230 (the “TDF Patents”). Teva asserted that the TDF patents 27 were invalid,…listed patent(s) and/or the patent is invalid and 10 unenforceable. Simply by listing the patents in the…ANDA applicant for patent 15 infringement. If the brand manufacturer brings a patent infringement action…legitimate patent protection or ferret out invalid, unenforceable, or 16 narrow drug patents. 17 18 …even after the 15 patents on them expired. 16 91. Gilead’s patents on TDF, FTC, and TDF | External link to document |
| 2019-08-22 | 118 | Complaint | 5,935,946; 5,977,089; and 6,043,230 (the “TDF Patents”). Teva asserted that the TDF patents 10 were invalid,…listed patent(s) and/or the patent is invalid and 23 unenforceable. Simply by listing the patents in the…ANDA applicant for patent 28 infringement. If the brand manufacturer brings a patent infringement action…applied for patents that 26 claim the formulation of TAF with FTC. See, e.g., United States Patent Application…Gilead’s patents protecting TAF can be divided into two groups: 7 Group Patent Patent | External link to document |
| 2023-05-19 | 1864 | Witness List | in U.S. Patent 14 Nos. 6,642,245 (’245 patent) and 6,703,396 (’396 patent…settling Lupin’s patent litigation over the FTC 26 Lupin patents. 27 … settling Cipla’s patent litigation over the FTC patents. Cipla 8 …pharmaceutical patent litigation gained over decades of working as a patent attorney…396 and ’245 patents 10 based on non-statutory double patenting over the claims | External link to document |
| 2023-06-26 | 2011 | Order | 15 6,703,396 (“the ʼ396 patent”) in the FDA publication “Approved Drug Products with… Gilead listed U.S. Patent No. 6,642,245 (“the ʼ245 patent”) and U.S. Patent No. … 21 patents and included a limited license to other patents, including the ’397 patent. …invention, or there is double-patenting (if what is claimed by the patent was patentably … 13 patents (i.e., the ‘264 and ‘397 patents), in the event Gilead sued Teva on those patents, and it | External link to document |
| 2023-06-27 | 2018 | Order | 15 6,703,396 (“the ʼ396 patent”) in the FDA publication “Approved Drug Products with… Gilead listed U.S. Patent No. 6,642,245 (“the ʼ245 patent”) and U.S. Patent No. … 21 patents and included a limited license to other patents, including the ’397 patent. …invention, or there is double-patenting (if what is claimed by the patent was patentably … 13 patents (i.e., the ‘264 and ‘397 patents), in the event Gilead sued Teva on those patents, and it | External link to document |
| 2020-04-21 | 304 | Amended Complaint | 5,977,089; and 6,043,230 (the “TDF Patents”). Teva asserted that the TDF patents were invalid, 9 …Gilead’s principal patents on TAF are Patent No. 7,390,791 (the ’791 Patent) and Patent 15 No. 7,803,…from the Patent and Trademark Office 4 (“PTO”) a patent-term extension on its principal patent on TAF…listed patent(s) and/or the patent is invalid and 11 unenforceable. Simply by listing the patents in the…the patent has issued. 35 U.S.C. § 156(c). The ’791 Patent issued in June 2008 and the ’788 Patent | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
